Arcalyst® (rilonacept)
| Full Name | Arcalyst® (rilonacept) |
| Drug | Arcalyst |
| Manufacturer | Kiniksa Pharmaceuticals (UK), Ltd. |
| Route of Administration | Subcutaneous |
| Site of Care | Home |
| Approved Indication | Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older; maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more; and treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older |
| Disease | Cryopyrin-Associated Periodic Syndromes (CAPS); Deficiency of Interleukin-1 Receptor Antagonist (DIRA); Recurrent Pericarditis (RP) |
| Therapeutic Area | Cardiology |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-473-3261 |
| Fax Number | 877-576-6745 |
| Product Website | arcalyst.com/hcp |